haematological cancers

View All

Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO.  A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve ...

Find More